Cargando…

Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study

BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Takayuki, Tanaka, Toshiaki, Yokoyama, Tadashi, Shimoyama, Takahiro, Ikeuchi, Hiroki, Uchino, Motoi, Watanabe, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298477/
https://www.ncbi.nlm.nih.gov/pubmed/28203278
http://dx.doi.org/10.1177/1756283X16679348
_version_ 1782505874113167360
author Yamamoto, Takayuki
Tanaka, Toshiaki
Yokoyama, Tadashi
Shimoyama, Takahiro
Ikeuchi, Hiroki
Uchino, Motoi
Watanabe, Toshiaki
author_facet Yamamoto, Takayuki
Tanaka, Toshiaki
Yokoyama, Tadashi
Shimoyama, Takahiro
Ikeuchi, Hiroki
Uchino, Motoi
Watanabe, Toshiaki
author_sort Yamamoto, Takayuki
collection PubMed
description BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospective study was to evaluate the efficacy of GMA for antibiotic-refractory pouchitis after proctocolectomy for UC. METHODS: A total of 13 patients with pouchitis disease activity index (PDAI) > 7 unresponsive to 2 weeks of antibiotic therapy were included. All patients received 10 GMA sessions at 2 sessions/week over 5 consecutive weeks. The primary endpoints were response (a decrease of ⩾3 points in the PDAI) and remission (PDAI < 4). Secondary endpoints included reduction of white blood cells (WBCs), C-reactive protein (CRP), faecal markers (calprotectin and lactoferrin), reduction of the PDAI endoscopic subscore, and GMA safety. RESULTS: The median PDAI score was significantly decreased from 11 (range, 9–15) at entry to 9 (range, 6–13) after the GMA therapy (p = 0.02). A total of six patients (46%) responded to the treatment, but none achieved remission. The median endoscopic subscore (maximum: 6) was 5 (range, 4–6) at entry and 5 (range, 1–6) after the treatment (p = 0.10). None of the laboratory markers (WBCs, CRP, faecal calprotectin and lactoferrin) significantly changed during the treatment. Transient adverse events (AEs) were observed in two patients (15%), dyspnoea in one and headache in one. The AEs were not serious, and all patients completed the 10 GMA sessions. CONCLUSIONS: GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy.
format Online
Article
Text
id pubmed-5298477
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-52984772017-02-15 Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study Yamamoto, Takayuki Tanaka, Toshiaki Yokoyama, Tadashi Shimoyama, Takahiro Ikeuchi, Hiroki Uchino, Motoi Watanabe, Toshiaki Therap Adv Gastroenterol Original Research BACKGROUND: Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospective study was to evaluate the efficacy of GMA for antibiotic-refractory pouchitis after proctocolectomy for UC. METHODS: A total of 13 patients with pouchitis disease activity index (PDAI) > 7 unresponsive to 2 weeks of antibiotic therapy were included. All patients received 10 GMA sessions at 2 sessions/week over 5 consecutive weeks. The primary endpoints were response (a decrease of ⩾3 points in the PDAI) and remission (PDAI < 4). Secondary endpoints included reduction of white blood cells (WBCs), C-reactive protein (CRP), faecal markers (calprotectin and lactoferrin), reduction of the PDAI endoscopic subscore, and GMA safety. RESULTS: The median PDAI score was significantly decreased from 11 (range, 9–15) at entry to 9 (range, 6–13) after the GMA therapy (p = 0.02). A total of six patients (46%) responded to the treatment, but none achieved remission. The median endoscopic subscore (maximum: 6) was 5 (range, 4–6) at entry and 5 (range, 1–6) after the treatment (p = 0.10). None of the laboratory markers (WBCs, CRP, faecal calprotectin and lactoferrin) significantly changed during the treatment. Transient adverse events (AEs) were observed in two patients (15%), dyspnoea in one and headache in one. The AEs were not serious, and all patients completed the 10 GMA sessions. CONCLUSIONS: GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy. SAGE Publications 2016-11-25 2017-02 /pmc/articles/PMC5298477/ /pubmed/28203278 http://dx.doi.org/10.1177/1756283X16679348 Text en © The Author(s), 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Yamamoto, Takayuki
Tanaka, Toshiaki
Yokoyama, Tadashi
Shimoyama, Takahiro
Ikeuchi, Hiroki
Uchino, Motoi
Watanabe, Toshiaki
Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
title Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
title_full Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
title_fullStr Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
title_full_unstemmed Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
title_short Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
title_sort efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298477/
https://www.ncbi.nlm.nih.gov/pubmed/28203278
http://dx.doi.org/10.1177/1756283X16679348
work_keys_str_mv AT yamamototakayuki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy
AT tanakatoshiaki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy
AT yokoyamatadashi efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy
AT shimoyamatakahiro efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy
AT ikeuchihiroki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy
AT uchinomotoi efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy
AT watanabetoshiaki efficacyofgranulocyteandmonocyteapheresisforantibioticrefractorypouchitisafterproctocolectomyforulcerativecolitisanopenlabelprospectivemulticentrestudy